1. Halozyme's CEO will present at TD Cowen Healthcare Conference. 2. The presentation is on March 5, 2025, at 8:50am PT. 3. Halozyme's ENHANZE® technology has impacted over one million patients. 4. The company partners with major pharma firms for drug delivery solutions. 5. Halozyme aims to improve patient experiences through innovative therapies.
The presentation at a major conference raises visibility, potentially attracting investor interest and partnerships. Historical examples show that companies gain favorable market responses from significant presentations or conferences, particularly when linked to innovative technologies.
The conference presentation can influence stock performance through potential investor engagement and market perception. With ongoing advancements in its technology, interest is likely to grow, boosting stock performance.
The upcoming conference date suggests immediate investor interest and price action. Recent conference presentations have often led to quick stock movement, thus indicating short-term significance.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the TD Cowen 45th Annual Healthcare Conference.
The presentation is scheduled for Wednesday, March 5 at 8:50am PT / 11:50am ET.
A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
[email protected]
Samantha Gaspar
Teneo
212-886-9356
[email protected]
SOURCE Halozyme Therapeutics, Inc.